SecBot SecBot

PEAT Act of 2026

H.R. 8630 Rep. Michael Rulli (R-OH-6) In committee
Bill text PDF
  1. Introduced Apr 30
  2. Committee Apr 30
  3. Passed House Next
  4. Passed Senate Not yet
  5. To President Not yet
  6. Law Not yet
Where it stands
In committee, Apr 30, 2026Next: House vote
181d ago Apr 30, 2026: Referred to the House Committee on Energy and Commerce.
Final votes
No roll callsNo recorded vote on this bill yet
Lobbying
1company, 1 filing
Subscribe to see spend
Member trades
2trades in the last 90 days
Subscribe to see who
Who backs the bill and who pushes back Subscribe

Companies lobbying on this bill

1 company
Companies by sector
Biotech & Pharma 1
Search all 1 companies, their asks and price moves Subscribe

Summary

This bill amends the Public Health Service Act to prohibit a biologic from being classified as a biological product solely because it contains a protein that is a clinically inactive component. Sec. 2, Prohibition with respect to treatment of proteins in biologics: The bill revises the definition of "biological product" in the Public Health Service Act to add a new provision stating that a biologic cannot be treated as a biological product based only on the presence of a protein that is a clinically inactive component in that biologic. It also makes a technical correction by removing a space before a comma in the existing definition.

Summary of the bill text as introduced in House (Apr 30, 2026), generated by SecBot from the official bill text; the Library of Congress summary is not yet published.

Official record from Congress.gov, the House Clerk and the Senate; lobbying from Lobbying Disclosure Act filings. Updated Oct 28, 2026.